Bottom line is we have two trials in Cancer and HI

Bottom line is we have two trials in Cancer and HIV that met their primary endpoints and will get approved. We know this is true. We have one more trial in Nash that we know met it’s primary endpoint in the 350mg open trial and the blinded trial should only yield better results. This makes 3 trials that should bring us a form of approval this year. Be it a BTD or BLA that is Fast Tracked or just a full duration BLA.

How can you not love the fact that we have in the bag in my opinion 3 different indications that it’s not “if”… it’s when… we get an approval and all in this calendar year 2022. Then quite possibly we can actually get a EUA for critical this year and maybe we get another BTD in Long Haulers or if not a BTD we just receive a BLA that might be the alternative path. Either way… chalk up another winner and all in this coming year 2022. What does this make? It looks like we could see 5 approvals of some kind with maybe even one more BTD in brain metastasis. That could possibly happen this year too for 6 approvals. Is there more out there? We know there is but probably not this year unless they hope a basket trial BTD happens but not likely this calendar year.

But here we sit at .70+ and waiting for the first catalyst to pop. Waiting for the pop in stock price. When you look at the big picture is it all that bad??? Does it seem like we don’t have anything to look forward to? Hell yes we do… we need to keep our eye fixed on the goals at hand. I think it’s just about sitting back and watching good things to start happening for us. Why? Because we are overdue for good things and we have paid our dues. It’s our time no matter how you look at it. Let’s get this done this year. Let’s see these indications through to the finish line. We have hired the best CRO’s and now is the time to get a return for our investment. It’s our time!